Citigroup Inc Bicycle Therapeutics PLC Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Citigroup Inc holds 668 shares of BCYC stock, worth $9,806. This represents 0.0% of its overall portfolio holdings.

Number of Shares

668

Previous 762 12.34%

Holding current value

$9,806

Previous $15,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$19.58 - $27.24 $1,840 - $2,560	-94 Reduced 12.34%	668 $15,000
Q2 2024 Aug 12, 2024	BUY	$20.02 - $24.69 $12,692 - $15,653	634 Added 495.31%	762 $15,000
Q1 2024 May 10, 2024	SELL	$16.75 - $26.1 $259,625 - $404,550	-15,500 Reduced 99.18%	128 $3,000
Q4 2023 Feb 09, 2024	BUY	$13.29 - $22.2 $200,625 - $335,131	15,096 Added 2837.59%	15,628 $282,000
Q3 2023 Nov 09, 2023	SELL	$19.9 - $26.25 $1,412 - $1,863	-71 Reduced 11.77%	532 $10,000
Q2 2023 Aug 10, 2023	BUY	$18.95 - $28.67 $2,804 - $4,243	148 Added 32.53%	603 $15,000
Q1 2023 May 11, 2023	SELL	$20.02 - $31.37 $1,121 - $1,756	-56 Reduced 10.96%	455 $9,000
Q4 2022 Feb 09, 2023	SELL	$20.37 - $32.9 $468 - $756	-23 Reduced 4.31%	511 $15,000
Q3 2022 Nov 10, 2022	SELL	$17.49 - $28.44 $961 - $1,564	-55 Reduced 9.34%	534 $12,000
Q2 2022 Aug 10, 2022	SELL	$12.95 - $46.99 $2,059 - $7,471	-159 Reduced 21.26%	589 $10,000
Q1 2022 May 12, 2022	SELL	$40.12 - $59.5 $2,166 - $3,213	-54 Reduced 6.73%	748 $33,000
Q4 2021 Feb 10, 2022	BUY	$41.7 - $61.14 $27,063 - $39,679	649 Added 424.18%	802 $49,000
Q3 2021 Nov 10, 2021	BUY	$27.95 - $44.24 $4,276 - $6,768	153 New	153 $6,000

Others Institutions Holding BCYC

# of Institutions

111

Shares Held

40.8M

Call Options Held

39.6K

Put Options Held

24.6K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $436M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account